HUSCAP logo Hokkaido Univ. logo

Hokkaido University Collection of Scholarly and Academic Papers >
医学研究院・医学院  >
雑誌発表論文等  >

The incidence and mechanism of sunitinib-induced thyroid atrophy in patients with metastatic renal cell carcinoma

BJC104-2_241-247.pdf1.23 MBPDF見る/開く

タイトル: The incidence and mechanism of sunitinib-induced thyroid atrophy in patients with metastatic renal cell carcinoma
著者: Shinohara, Nobuo 著作を一覧する
Takahashi, Masayuki 著作を一覧する
Kamishima, Tamotsu 著作を一覧する
Ikushima, Hitoshi 著作を一覧する
Otsuka, Noriyuki 著作を一覧する
Ishizu, Akihiro 著作を一覧する
Shimizu, Chikara 著作を一覧する
Kanayama, Hiroomi 著作を一覧する
Nonomura, Katsuya 著作を一覧する
キーワード: thyroid atrophy
renal cell carcinoma
発行日: 2011年 1月18日
出版者: Nature Publishing Group
誌名: British Journal of Cancer
巻: 104
号: 2
開始ページ: 241
終了ページ: 247
出版社 DOI: 10.1038/sj.bjc.6606029
抄録: Background: In order to elucidate the incidence and the mechanisms of sunitinib-induced thyroid atrophy, we investigated the serial volumetric and functional changes, and evaluated histological changes of the thyroid gland in metastatic renal cell carcinoma patients who received sunitinib. Methods: Thyroid volume measured by CT volumetry and thyroid function were measured at baseline, during the treatment, and at post-treatment periods. Histological evaluation of thyroid gland was performed in 4 autopsied patients. Results: The median reduction rate in thyroid volume at last evaluation during sunitinib treatment was 30% in all 17 patients. The incidence of hypothyroidism during sunitinib treatment was significantly higher in the high reduction rate group (n=8; more than 50% reduction in volume) than in the low reduction rate group (n=9; less than 50% reduction in volume). Half of patients in the high reduction rate group exhibited a transient TSH suppression suggesting thyrotoxicosis during sunitinib treatment. Histological evaluation demonstrated atrophy of thyroid follicles and degeneration of follicular epithelial cells without critical diminution of vascular volume in the thyroid gland. Conclusion: Thyroid atrophy is frequently observed following sunitinib treatment and may be brought about by sunitinib-inuced thyrotoxicosis or the direct effects of sunitinib that leads to degeneration of thyroid follicular cells.
資料タイプ: article (author version)
出現コレクション:雑誌発表論文等 (Peer-reviewed Journal Articles, etc)

提供者: 篠原 信雄


本サイトに関するご意見・お問い合わせは repo at へお願いします。 - 北海道大学